107 related articles for article (PubMed ID: 25940438)
1. Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.
Zagryazhskaya A; Surova O; Akbar NS; Allavena G; Gyuraszova K; Zborovskaya IB; Tchevkina EM; Zhivotovsky B
Oncotarget; 2015 May; 6(14):12156-73. PubMed ID: 25940438
[TBL] [Abstract][Full Text] [Related]
2. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.
Liu X; Ma M; Duan X; Zhang H; Yang M
Clin Transl Oncol; 2017 May; 19(5):587-592. PubMed ID: 27832473
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
6. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells.
Zheng MD; Wang ND; Li XL; Yan J; Tang JH; Zhao XH; Zhang Z
J Nat Med; 2018 Jun; 72(3):724-733. PubMed ID: 29627895
[TBL] [Abstract][Full Text] [Related]
7. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
8. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression.
Wang HQ; Jin JJ; Wang J
J Biochem Mol Toxicol; 2014 Jan; 28(1):39-45. PubMed ID: 24395429
[TBL] [Abstract][Full Text] [Related]
9. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
11. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.
Jin HO; Hong SE; Woo SH; Lee JH; Choe TB; Kim EK; Noh WC; Lee JK; Hong SI; Kim JI; Park IC
Cell Death Dis; 2012 Jun; 3(6):e319. PubMed ID: 22673193
[TBL] [Abstract][Full Text] [Related]
12. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
13. In vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of non-small cellular lung cancer cells.
Gansukh T; Donizy P; Halon A; Lage H; Surowiak P
Anticancer Res; 2013 Dec; 33(12):5255-60. PubMed ID: 24324058
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
Fujita Y; Yagishita S; Takeshita F; Yamamoto Y; Kuwano K; Ochiya T
Oncotarget; 2015 Feb; 6(5):3335-45. PubMed ID: 25595901
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.
Duan L; Shen H; Zhao G; Yang R; Cai X; Zhang L; Jin C; Huang Y
Biochem Biophys Res Commun; 2014 Apr; 446(4):1010-6. PubMed ID: 24657266
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
[TBL] [Abstract][Full Text] [Related]
20. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
